VYNE Therapeutics Inc (VYNE): Growth-Adjusted Market Cap to Net Income

Corporate company logo of vynetherapeutics.com (VYNE)

VYNE Therapeutics seeks synergy through clinic partnerships and patent acquisitions. The current PEG ratio illustrates the progress of this strategy, with the metric standing at 0.00. However, the implementation of eco-packaging and toxicity control create operational expenses, although a stable US market and the absence of sanctions minimize external risks for the business.

PEG Multiple: VYNE Therapeutics Inc (VYNE) for 07/04/2022 - 07/28/2026

VYNE Therapeutics Inc. (VYNE) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Summary company analytics:VYNE - VYNE Therapeutics
Manufactured products of vynetherapeutics.com

A value below one signals that the asset is undervalued, as the PEG ratio correlates the P/E market multiple with the rate of business expansion. By analyzing the P/E trend relative to growth, an investor can assess the extent to which the effectiveness of the proprietary MST technology in psoriasis therapy is reflected in the current share price of VYNE Therapeutics (VYNE) relative to its scaling rates.